ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BCRX BioCryst Pharmaceuticals Inc

6.52
-0.05 (-0.76%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioCryst Pharmaceuticals Inc NASDAQ:BCRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -0.76% 6.52 6.47 6.55 6.815 6.43 6.63 3,831,914 23:36:17

BioCryst to Present at Upcoming Investor Conferences

07/05/2024 12:00pm

GlobeNewswire Inc.


BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart


From May 2024 to Jun 2024

Click Here for more BioCryst Pharmaceuticals Charts.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:

  • Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET.
  • 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET.
  • Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday, May 20, 2024, at 10:30 a.m. ET.
  • Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024, at 9:30 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:John Bluth+1 919 859 7910jbluth@biocryst.com

1 Year BioCryst Pharmaceuticals Chart

1 Year BioCryst Pharmaceuticals Chart

1 Month BioCryst Pharmaceuticals Chart

1 Month BioCryst Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock